Presentation is loading. Please wait.

Presentation is loading. Please wait.

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity 

Published byOpal Dickerson Modified over 5 years ago

Similar presentations

Presentation on theme: "Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity "— Presentation transcript:

1 Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity  Giorgio Ciprandi, MD, Caterina Pronzato, MD, Giovanni Passalacqua, MD, Vittorio Ricca, MD, Jan Grögen, G.S. Mela, Paolo Varese, MD, Claudia Bertolini, MD, Marcello Bagnasco, MD, Giorgio Walter Canonica, MD  Journal of Allergy and Clinical Immunology  Volume 98, Issue 6, Pages (December 1996) DOI: /S (96) Copyright © 1996 Mosby, Inc. Terms and Conditions

2 FIG. 1 Patients’ total symptom scores after specific allergen nasal challenge, evaluated at T0 and T7. Median values are represented by thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

3 FIG. 1 Patients’ total symptom scores after specific allergen nasal challenge, evaluated at T0 and T7. Median values are represented by thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

4 FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

5 FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

6 FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

7 FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

8 FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

9 FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

10 FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

11 FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

12 FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

13 FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

14 FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

15 FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

16 FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

17 FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

18 FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

19 FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

Download ppt "Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity "

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Shin-Ichi Nishikawa, MD, PhD 

Shin-Ichi Nishikawa, MD, PhD 
Serum cytotoxic T lymphocyte–associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy  Daniele Saverino, BS, Anna.

Serum cytotoxic T lymphocyte–associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy  Daniele Saverino, BS, Anna.
Allergic Rhinitis and Its Impact on Asthma

Allergic Rhinitis and Its Impact on Asthma
Ulf Darsow, MD, Dieter Vieluf, MD, Johannes Ring, MD, PhD 

Ulf Darsow, MD, Dieter Vieluf, MD, Johannes Ring, MD, PhD 
Damage of the pharyngeal mucosa and hyperresponsiveness of airway in sinusitis  Giovanni Rolla, MDa, Paola Colagrande, MDa, Ermanno Scappaticci, MDb, Flavia.

Damage of the pharyngeal mucosa and hyperresponsiveness of airway in sinusitis  Giovanni Rolla, MDa, Paola Colagrande, MDa, Ermanno Scappaticci, MDb, Flavia.
The effect of omalizumab on nasal allergic inflammation

The effect of omalizumab on nasal allergic inflammation
Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation  Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,

Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation  Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,
Youngil I. Koh, MD a, Inseon S

Youngil I. Koh, MD a, Inseon S
Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.
Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD 

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD 
Practice Notes from the AAAI

Practice Notes from the AAAI
Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the.

Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the.
Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.
Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,
Noninjection routes for immunotherapy

Noninjection routes for immunotherapy
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis 

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis 
Elephantiasis nostras: A case report

Elephantiasis nostras: A case report

Similar presentations

Ads by Google